ClinicalTrials.gg
Active, not recruitingNCT07107945Updated Nov 10, 2026

A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

A Phase 3 interventional study of Empagliflozin and Placebo in Chronic Kidney Disease, sponsored by Boehringer Ingelheim. Active, not recruiting at 93 sites in 18 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Updated Nov 5, 2026Now Active, not recruitingEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing empagliflozin in Renal Insufficiency, Chronic — 6 open to participants now, 7 under way, 1 of them phase 3. empagliflozin · Renal Insufficiency, Chronic.

Enrollment
7th of 20
135 · median 77
Started
2025
with 2 others
Phase 3
2 of 20
none open now
Registered
17th of 20
by date
Lead sponsor
4 of 20
Boehringer Ingelheim

Among the 20 studies testing empagliflozin in Renal Insufficiency, Chronic, this one is the 7th largest by enrollment, is one of 3 that started in 2025, is one of 2 in phase 3, and was the 17th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

6 of the 20 studies testing empagliflozin in Renal Insufficiency, Chronic are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing empagliflozin in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD. Other goals of the study are to find out how empagliflozin is tolerated and handled by the body in children and adolescents with CKD.

Participants are put into 2 groups randomly, which means by chance. One group takes empagliflozin and the other group takes placebo. Placebo looks like empagliflozin but does not contain any medicine. Participants are twice as likely to be in the empagliflozin group. Participants take empagliflozin or placebo as tablets once a day for 6 months. After 6 months, participants in both groups take empagliflozin as tablets once a day for 1 year.

Participants are in the study for a little over a year and a half. During this time, they visit the study site about 15 times and get at least 5 phone or video calls from the site staff. At the visits, the doctors take blood and urine samples from the participants. The doctors also regularly check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Chronic Kidney Disease
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated written provided by the patient's parent(s) (or legal guardian) and patient's assent in accordance with international council for harmonisation good clinical practice (ICH-GCP) and local legislation prior to admission to the trial (informed assent will be sought according to the patient's age, level of maturity, competence, and capacity).
  • Age 2 to 17 years at screening Visit 1.
  • Chronic kidney disease (CKD) of any underlying aetiology defined by (as measured by central laboratory at screening Visit 1): estimated (eGFR) (U25Crea) ≥20 to \<90 mL/min/1.73 m2 with a urine-albumine-creatinine (UACR) ≥300 mg/g
  • Participants must be on a stable dose of maximally tolerated standard of care (SoC) therapy for 30 days before screening visit 1 with no plans to change the dose throughout the duration of the placebo-controlled duration of the trial. SoC is anticipated to include a single Renin-angiotensin-aldosterone system (RAAS) inhibitor, such as angiotensin receptor blockers (ARB) or angiotensin converting enzyme inhibitors (ACEi) as appropriate and tolerated. Additional use of a mineralocorticoid receptor antagonist (MRA, including finerenone if available) is permitted if needed and the dose is stable for 30 days before screening Visit 1 and no planned dose changes for the placebo-controlled portion of the trial.
  • Participants receiving daily therapy for an underlying immunological cause of CKD must be on a stable dose for the duration specified for each drug prior to screening and must remain on a stable regimen throughout the placebo-controlled portion of the trial.
  • Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Confirmed type 1 or type 2 diabetes mellitus.
  • History of ketoacidosis within 8 weeks prior to Visit 1 and up to randomisation.
  • Chronic dialysis or functioning kidney transplant or scheduled for transplantation throughout the duration of the trial.
  • Diagnosis of uncontrolled metabolic bone disease (at the Investigator's discretion).
  • (BMI) ≤10th percentile for children ≥4 years of age and ≤25th percentile for children \<4 years of age according to Centers for Disease Control and Prevention (CDC) growth chart at screening Visit 1.
  • Gastrointestinal disorders that might interfere with trial drug absorption according to investigator assessment.
  • Presence of acute or active urinary tract infection (UTI) with signs or symptoms of an active UTI or therapeutic treatment for an active UTI within 14 days before screening Visit 1.
  • Severe, uncontrolled hypertension (based on investigator's judgement).
  • Further exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Empagliflozin treatment arm

    Drug: Empagliflozin

  • Placebo comparator
    Placebo arm

    Drug: Placebo

Interventions

  • Empagliflozin

    Also known as: Jardiance

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change from Day 1 to the Week 24 visit in urine albumin-creatinine (UACR) [mg/g]

    Time frame: Up to week 24

  2. Change from Day 1 to the Week 24 visit in urine glucose [mmol/L]

    Time frame: Up to week 24

Secondary outcomes

  1. Change in estimated glomerular filtration rate (eGFR) (U25Crea) over time during treatment with empagliflozin

    U25Crea = estimates the glomerular filtration rate based on creatinine in patients aged up to 25 years

    Time frame: Up to week 73

  2. Annual rate of change in eGFR (U25Crea) from the Week 8 to the Week 24 visit, including treatment effect extrapolation from (adult) EMPA-KIDNEY data

    Time frame: Up to week 24

  3. Change from Day 1 to the Week 24 visit in urine protein-creatinine ratio (UPCR)

    Time frame: Up to week 24

  4. The observed predose plasma concentrations of empagliflozin at the Week 26 visit

    Time frame: Up to week 26

  5. Occurrence of at least one SAE or AE of special interest (AESI) per participant between Day 1 and the Week 24 visit, and between the Week 24 visit and end of treatment (EoT) +7 days residual effect period (REP)

    SAE= serious adverse event AE= adverse event

    Time frame: Up to week 73

07

Study locations

93 sites
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Apr 2027, 16 months after the start.

Of 104 industry-sponsored phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 49. This study's planned 16 months is below that.

Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Aug 6, 2025
StartActual
Dec 9, 2025
Primary completionEst.
Apr 16, 2027
CompletionEst.
Apr 14, 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 14, 2026
Sites
2 sites added, 2 sites removed
Show 2 added (1 Sweden, 1 Spain)
  • Sahlgrenska Universitetssjukhuset, Östra · Gothenburg, Sweden
  • Hospital Universitario Virgen del Rocio · Seville, Spain
Show 2 removed
  • Sahlgrenska Universitetssjukhuset, Ostra · Gothenburg, Sweden
  • Hospital Virgen del Rocio · Seville, Spain
across 2 updates, Oct 14, 2026 – Nov 5, 2026
Enrollment
120 (estimated)→135 (actual)
Oct 14, 2026
Show all 2 updates
  1. Nov 5, 2026
    1 site added, 1 site removed
    Show site
    • Hospital Universitario Virgen del Rocio · Seville, Spain
    Show 1 removed
    • Hospital Virgen del Rocio · Seville, Spain
    + 1 other change: verification date
  2. Oct 14, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • Sahlgrenska Universitetssjukhuset, Östra · Gothenburg, Sweden
    Show 1 removed
    • Sahlgrenska Universitetssjukhuset, Ostra · Gothenburg, Sweden
    Enrollment 120 (estimated)→135 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07107945
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Dec 9, 2025
Primary completion
Apr 16, 2027 (estimated)
Completion
Apr 14, 2028 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion